Drug eluting that can inhibit vascular smooth muscle cells proliferation and neointimal hyperplasia, with no affection on vascular endothelial healing is a new strategy to develop novel drug eluting stent and to prevent in-stent restenosis.OBJECTIVE:
To summarize advanced progress on drug-eluting stent that prevents vascular smooth muscle cell proliferation and migration.METHODS:
An online computer-based retrieval was performed by the first author on VIP database for articles regarding the drug-eluting stent of anti-vascular smooth muscle cells proliferation and migration in the treatment of cardiovascular disease, retrieval time ranged from January 1998 to October 2011. Key words were “cardiovascular diseases; drug-eluting stents; vascular smooth muscle cells; cell proliferation; cell migration” in Chinese. After the primary screening, all citations of each literature were checked. A total of 25 literatures were involved, including 15 Chinese and 10 English.RESULTS AND CONCLUSION:
The currently used eluting drugs of anti-vascular smooth muscle cells proliferation and migration are rapamycin and paclitaxel. An increasing number of studies show that, rapamycin and paclitaxel in corresponding stents can both effectively reduce restenosis after stent implantation and rate of target vessel blood supply revascularization in clinical practice. Most of the current domestic research are small sample size, single-center, non-randomized controlled trials, and long-term efficacy and safety need to longer-term follow-ups and multicenter randomized controlled study.RESULTS AND CONCLUSION:
Zhang ZP, Ge H. Drug eluting against vascular smooth muscle proliferation and migration for in-stent restenosis. Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(12): 2245-2248.